Opened 1447 days ago
Closes 31 December 2022
Trial Aim Description
Testing a potential new treatment/investigational product for (Inclusion Body Myositis) IBM. The potential new treatment/investigational product is called ABC008.
Trial Eligibility Requirements
Patients must be living with inclusion body myositis (IBM)
Interested? Enquire today
Principal Investigator: Professor Merrilee Needham
Enquiries Email: k.beer@iiid.murdoch.edu.au